FATE: Fate Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 144.65
Enterprise Value ($M) 106.74
Book Value ($M) 362.33
Book Value / Share 3.18
Price / Book 0.40
NCAV ($M) 177.65
NCAV / Share 1.56
Price / NCAV 0.81

Profitability (mra)
Return on Invested Capital (ROIC) -0.39
Return on Assets (ROA) -0.35
Return on Equity (ROE) -0.48

Liquidity (mrq)
Quick Ratio 8.29
Current Ratio 8.29

Balance Sheet (mrq) ($M)
Current Assets 310.29
Assets 494.97
Liabilities 132.64
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-14 13G/A Point72 Asset Management, L.P. 0.00 -100.00
11-08 13G/A BlackRock, Inc. 9.20 0.00
10-25 13G/A Boxer Capital Management, LLC 4.40
03-25 13D/A Redmile Group, LLC 14.90 17.07
02-13 13G/A Vanguard Group Inc 9.43 -6.47
02-12 13G Boxer Capital, LLC 6.30
02-09 13G/A Capital World Investors 0.00 -100.00
2024-01-22 13G/A State Street Corp 1.89 -18.05

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-21 300,151 820,786 36.57
2025-01-17 365,913 1,142,591 32.02
2025-01-16 578,622 1,587,427 36.45

(click for more detail)

Similar Companies
ESPR – Esperion Therapeutics, Inc. ETNB – 89bio, Inc.
ETON – Eton Pharmaceuticals, Inc. FBLG – FibroBiologics, Inc.
FHTX – Foghorn Therapeutics Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Fate Therapeutics